Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KineMed renews diabetes collaboration with Pfizer
May 2013
SHARING OPTIONS:

EMERYVILLE, Calif.KineMed Inc. has renewed its non-exclusive research collaboration with Pfizer Inc. for accelerating novel approaches toward metabolic disease, specifically type II diabetes. The partners will make use of KineMed's dynamic proteomics technology platform to determine the effects of potential drug candidates on select metabolic pathways.  
 
"We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform," commented Dr. Scott Turner, executive vice president of R&D at KineMed. "We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in preclinical and clinical trials."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.